Are the two human papillomavirus vaccines really similar? A systematic review of available evidence: efficacy of the two vaccines against HPV
S Di Mario, V Basevi, PL Lopalco… - Journal of …, 2015 - Wiley Online Library
Background. When the bivalent and the quadrivalent HPV vaccines were marketed they
were presented as having comparable efficacy against cervical cancer. Differences between …
were presented as having comparable efficacy against cervical cancer. Differences between …
Direct comparison of HPV16 serological assays used to define HPV-naive women in HPV vaccine trials
M Safaeian, A Ghosh, C Porras, SW Lin… - … , biomarkers & prevention, 2012 - AACR
Background: Two HPV serological assays, the competitive Luminex immunoassay (cLIA),
and an enzyme-linked immunoassay (ELISA) against HPV16 have been used to define HPV …
and an enzyme-linked immunoassay (ELISA) against HPV16 have been used to define HPV …
[HTML][HTML] HPV infections and cytologic abnormalities in vaccinated women 21–34 years of age: Results from the baseline phase of the Onclarity trial
TC Wright Jr, V Parvu, MH Stoler, S Kodsi, K Eckert… - Gynecologic …, 2019 - Elsevier
Objectives Countries with school-based human papillomavirus (HPV) vaccination have seen
significant reductions in vaccine-targeted HPV infections, cytologic abnormalities, and high …
significant reductions in vaccine-targeted HPV infections, cytologic abnormalities, and high …
Efficacy and safety of prophylactic HPV vaccines. A Cochrane review of randomized trials
M Arbyn, L Xu - Expert review of vaccines, 2018 - Taylor & Francis
Introduction: Recently, the evidence on efficacy and safety of prophylactic HPV vaccines
derived from randomized trials was published in the Cochrane database of Systematic …
derived from randomized trials was published in the Cochrane database of Systematic …
Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial
WK Huh, EA Joura, AR Giuliano, OE Iversen… - The Lancet, 2017 - thelancet.com
Background Primary analyses of a study in young women aged 16–26 years showed
efficacy of the nine-valent human papillomavirus (9vHPV; HPV 6, 11, 16, 18, 31, 33, 45, 52 …
efficacy of the nine-valent human papillomavirus (9vHPV; HPV 6, 11, 16, 18, 31, 33, 45, 52 …
Efficacy of human papillomavirus vaccines: a systematic quantitative review
LR Medeiros, DD Rosa, MI Da Rosa… - International Journal of …, 2009 - ijgc.bmj.com
Human papillomavirus (HPV) types cause approximately 70% of cervical cancer worldwide.
Two vaccines have been recently evaluated in randomized controlled trials: the bivalent …
Two vaccines have been recently evaluated in randomized controlled trials: the bivalent …
The distribution and pathogenic risk of non‐9‐valent vaccine covered HPV subtypes in cervical lesions
M Ma, J Zhu, Y Yang, X Wang, Y Jin, J Zhang… - Cancer …, 2022 - Wiley Online Library
Human papillomavirus (HPV) infection is the main cause of female precancerous lesions
and cervical cancer. The development and application of HPV prophylactic vaccines have …
and cervical cancer. The development and application of HPV prophylactic vaccines have …
Impact of 2-, 4-and 9-valent HPV vaccines on morbidity and mortality from cervical cancer
R Luckett, S Feldman - Human vaccines & immunotherapeutics, 2016 - Taylor & Francis
Cervical cancer causes significant morbidity and mortality worldwide. Most cervical cancers
are associated with oncogenic human papillomavirus (HPV), and vaccination with any of 3 …
are associated with oncogenic human papillomavirus (HPV), and vaccination with any of 3 …
Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared to the licensed 3-dose schedule: Results from a …
B Romanowski, TF Schwarz, LM Ferguson… - Human …, 2011 - Taylor & Francis
The immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine
(Cervarix®, GlaxoSmithKline Biologicals) administered according to its licensed vaccination …
(Cervarix®, GlaxoSmithKline Biologicals) administered according to its licensed vaccination …
Long‐term effectiveness of HPV vaccination against HPV infection in young Japanese women: Real‐world data
M Kurosawa, M Sekine, M Yamaguchi, R Kudo… - Cancer …, 2022 - Wiley Online Library
In Japan, public funding for HPV vaccination began in 2010 for girls aged 13–16 years (birth
cohort years 1994–1997) and women born in 1994 who turned 25 in 2019. We aimed to …
cohort years 1994–1997) and women born in 1994 who turned 25 in 2019. We aimed to …